Status: Recruiting
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Participants needed: 64
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: Peter Ljubenkov, MDUpdated: Oct 15, 2025Locations: 5
Eligibility criteria
Between 18 and 85 years of age (inclusive) at the initial screening visit; [+6]
Has a reliable study partner who agrees to accompany the participant to visits,... [+38]